[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608475":3},{"organization":4,"outcomesModule":7,"designInfo":37,"detailedDescription":36,"studyPopulation":36,"armGroups":43,"interventions":59,"overallOfficials":36,"centralContacts":65,"locations":71,"responsibleParty":91,"collaborators":96,"id":100,"slug":36,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":101,"sex":106,"minAge":107,"maxAge":36,"enrollmentInfo":108,"targetDuration":36,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":74,"whyStopped":36,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"Prisma Health-Upstate","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":36},[9],{"measure":10,"description":11,"timeFrame":12},"Change in cigarettes smoked per day","The average change in mean CPD on a 7-day TLFB assessment from baseline (week 0) to weeks 12","Baseline to week 12",[14,17,21,25,28,32],{"measure":10,"description":15,"timeFrame":16},"The average change in mean CPD on a 7-day TLFB assessment from baseline (week 0) to week 24","Baseline to week 24",{"measure":18,"description":19,"timeFrame":20},"Percentage of participants with a ≥50% reduction in CPD","The rate of participants achieving an average ≥50% reduction in CPD from baseline (week 0) to weeks 12 and 26, based on a 7-day TLFB","Baseline to weeks 12 and 26",{"measure":22,"description":23,"timeFrame":24},"Switching","Proportion of participants reporting exclusive EC use and no CC use on a 7-day TLFB with CO \\\u003C6 ppm.","Weeks 12 and 24",{"measure":26,"description":27,"timeFrame":24},"Partial Switching","Proportion of participants reporting both EC and CC use on a 7-day TLFB with a ≥50% reduction in CPD.",{"measure":29,"description":30,"timeFrame":31},"7-Day CC Abstinence","Percentage of participants with biochemically verified 7-day abstinence (1 = abstinent, 0 = non-abstinent). Defined as self-reported no CC use on a 7-day TLFB with CO \\\u003C6 ppm.","Weeks 12 and 26",{"measure":33,"description":34,"timeFrame":35},"Change in carbon monoxide levels","Change in exhaled CO levels from baseline (week 0) to weeks 12 and 26 (continuous variable).","Baselone to weeks 12 and 26",null,{"allocation":38,"interventionModel":39,"interventionModelDescription":36,"primaryPurpose":40,"observationalModel":36,"timePerspective":36,"maskingInfo":41},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":42,"maskingDescription":36,"whoMasked":36},"NONE",[44,50,54],{"label":45,"type":46,"description":47,"interventionNames":48},"Sweet-Cooling EC + Counseling","EXPERIMENTAL","Those randomized to the intervention group will be provided a free 12-week supply of sweet-cooling electronic cigarette (EC) liquid and five brief, individual counseling sessions, and asked to try to switch completely to EC.",[49],"Behavioral: Brief individual counseling sessions",{"label":51,"type":46,"description":52,"interventionNames":53},"Sweet non-cooling EC + Counseling","Those randomized to the intervention group will be provided a free 12-week supply of sweet non-cooling electronic cigarette (EC) liquid and five brief, individual counseling sessions, and asked to try to switch completely to EC.",[49],{"label":55,"type":56,"description":57,"interventionNames":58},"Tobacco-flavored EC + Counseling","ACTIVE_COMPARATOR","Those randomized to the intervention group will be provided a free 12-week supply of tobacco-flavored electronic cigarette (EC) liquid and five brief, individual counseling sessions, and asked to try to switch completely to EC.",[49],[60],{"type":61,"name":62,"description":63,"armGroupLabels":64,"otherNames":36},"BEHAVIORAL","Brief individual counseling sessions","Five brief, individual counseling sessions will provide education, behavioral support, and motivational strategies to facilitate switching from combustible cigarette use to EC",[51,45,55],[66],{"name":67,"role":68,"phone":69,"phoneExt":36,"email":70},"Irene Pericot-Valverde, PhD","CONTACT","(864)656-4467","iperico@clemson.edu",[72],{"facility":73,"status":74,"city":75,"state":76,"zip":77,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":85,"contacts":86},"Addiction Medicine Center","RECRUITING","Greenville","South Carolina","29605","United States","US",{"type":81,"coordinates":82},"Point",[83,84],-82.39401,34.85262,{"lat":84,"lon":83},[87],{"name":88,"role":68,"phone":89,"phoneExt":36,"email":90},"Alain Litwin, MD","864-455-5648","alain.litwin@prismahealth.org",{"type":92,"investigatorFullName":93,"investigatorTitle":94,"investigatorAffiliation":95,"oldNameTitle":36,"oldOrganization":36},"PRINCIPAL_INVESTIGATOR","Irene Pericot-Valverde","Assistant Professor","Clemson University",[97],{"name":98,"class":99},"National Institute on Drug Abuse (NIDA)","NIH","100608475",false,"NCT07202039","Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine","SWITCH","Inclusion Criteria\n\n* Age ≥21 years\n* Smoke ≥5 CPD for ≥1 year\n* Daily CC smoker\n* Willing to switch to EC\n* Exhaled CO ≥6 ppm\n* Diagnosed with OUD\n* Stable on bupropion treatment\n* In good physical and mental health\n* Able to use a smartphone\n* Willing to participate in all study components\n* Able to provide informed consent Exclusion Criteria\n* Interested in quitting CC (contemplation stage of change)\n* Use of EC on ≥4 of the past 30 days\n* Use of other tobacco products (e.g., cigars, smokeless tobacco) on ≥9 days of the past 30 days\n* Use of nicotine replacement therapy, smoking cessation medication, or a cessation attempt in the past 30 days\n* Hypertension\n* Medical condition that would contraindicate participation\n* Meet DSM-V criteria for major depressive episode, psychotic episode, or manic episode\n* Current suicidal ideation or suicide attempt in the past year\n* Psychiatric hospitalization in the past year\n* Contemplating pregnancy, currently pregnant, or breastfeeding\n* Unable to speak and\u002For read English","ALL","21 Years",{"count":109,"type":110},90,"ESTIMATED","INTERVENTIONAL",[113],"NA","This project aims to investigate the impact of e-cigarette flavors and usage patterns on achieving harm-reduction milestones in a sample of cigarette smokers with opioid use disorder who are taking buprenorphine",[116,117,118],"Tobacco-flavored EC","Sweet-Cooling EC","Sweet Non-cooling EC",[120,121,122,123,22,124],"Cigarette Smoking","Opioid use disorder","Burprenorphine","Electronic cigarettes","Flavors","2026-05-11",{"date":127,"type":128},"2026-05-12","ACTUAL",{"date":130,"type":128},"2026-04-29",{"date":132,"type":110},"2029-06-29",{"name":5,"class":6},1]